生产企业：Takeda Pharmaceutical
Oveporexton (TAK-861; brand name Orzeyful) is an oral, orexin receptor 2-selective agonist developed by Takeda Pharmaceutical. It is the first approved drug designed to replace orexin, the brain peptide missing in people with narcolepsy type 1.
Oveporexton (TAK-861; brand name Orzeyful) is an oral, orexin receptor 2-selective agonist developed by Takeda Pharmaceutical. It is the first approved drug designed to replace orexin, the brain peptide missing in people with narcolepsy type 1.
Oveporexton is an oral orexin receptor 2 (OX2R) agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1 (NT1).
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
